A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-06-08
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-08 (study day 11); relationship: not assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 82); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-18 (study day 83); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-01-18 (study day 205); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-05-07 (study day 315); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-07-03 (study day 372); relationship: N
Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2024-10-28 (study day 489); relationship: N
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-12-30 (study day 552); relationship: not assessed
Data queries
No data queries.